Systemic drug therapy and restenosis after drug-eluting stent implantation / 대한내과학회지
Korean Journal of Medicine
;
: 366-367, 2008.
Article
in Korean
| WPRIM
| ID: wpr-194465
ABSTRACT
Until now restenosis is one of the most important issues after stent implantation. Use of systemic drug therapy to inhibit post-stent restenosis has been largely unsuccessful. Drug-eluting stents (DES) have been shown to significantly reduce restenosis after percutaneous coronary intervention. However we still experience lots of problems associated with restenosis even after DES implantation. Recently some clinical trials have suggested that cilostazol reduces intimal hyperplasia and lowers restenosis after bare metal stents (BMS) implantation. It is uncertain that cilostazol can also reduce restenosis after DES implantation. We need more large clinical trials to elucidate the efficacy of cilostazol on restenosis after DES implantation.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Tetrazoles
/
Stents
/
Drug-Eluting Stents
/
Percutaneous Coronary Intervention
/
Hyperplasia
Language:
Korean
Journal:
Korean Journal of Medicine
Year:
2008
Type:
Article
Similar
MEDLINE
...
LILACS
LIS